In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (11/2010)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Look For A Place In Coming Hepatitis C Combo Regimens." features profiles of AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus. Plus these Start-Ups Across Health Care: Arineta, HemoShear, Hygieia and Silver Bullet Therapeutics.

You may also be interested in...



Hygieia Inc.

An urgent need exists for a simple and cost-effective way to support insulin therapy, mainly for people with type 2 diabetes, in between physician check-ups. Hygieia Inc. plans on addressing this need in a big way with its patient- and clinician-friendly Diabetes Insulin Guidance System (DIGS), designed to replace commonly used glucose meters that simply provide blood sugar readings. Hygieia's DIGS device is designed to support diabetes patients' glycemic control by providing them with with simple dose-by-dose insulin recommendations.

Arineta Ltd.

Instead of relying on a conventional whole-body computed tomography scan in a hospital setting for cardiac imaging, cardiologists could someday have a smaller, lighter and less expensive CT system in their own office. Israeli-based Arineta Ltd. is developing just such a dedicated cardiovascular CT device.

AiCuris GMBH & Co. KG

With seven molecules in clinical development, another three preclinical compounds approaching the clinic, and a half-dozen discovery programs divided equally between virology and bacteriology, AiCuris is seeking the keys to thwarting viral replication. The start-up has drug candidates targeting herpes simplex virus, human cytomegalovirus and hepatitis C.

Related Content

Related Companies

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel